BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12822405)

  • 1. [Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia].
    Tabata S; Ohno T; Tomo K; Hishita T; Hada S; Mizumoto T; Furukawa H
    Rinsho Ketsueki; 2003 May; 44(5):313-7. PubMed ID: 12822405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].
    Meng FY; Sun J; Liu QF; Xu D; Yang LJ; Song LL; Liu XL; Xu B; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Dec; 23(12):1301-2, 1306. PubMed ID: 14678896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
    Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H
    Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study].
    Liu L; Liu Q; Hao MW; Chen RA; Zhang JL; Wang LH; He H; Jiang SS; Liang YM
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1102-5. PubMed ID: 16029566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Autologous transplantation of Ph-negative peripheral blood stem cells for treatment of chronic myelogenous leukemia].
    Hatsuse M; Okano A; Okamoto A; Shimura K; Takahashi R; Hirai H; Ashihara E; Inaba T; Fujita N; Shimazaki C; Nakagawa M
    Rinsho Ketsueki; 2000 Aug; 41(8):671-5. PubMed ID: 11020996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
    Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
    Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
    Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
    Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
    Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
    Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
    Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
    Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
    Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
    Jin Huh H; Won Huh J; Myong Seong C; Lee M; Soon Chung W
    Am J Hematol; 2003 Nov; 74(3):218-20. PubMed ID: 14587058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful induction of complete cytogenetic response with high-dose imatinib mesylate and subsequent allogeneic stem cell transplantation for CML blastic crisis].
    Sugiyama K; Usui N; Asai O; Saito T; Yano S; Okawa Y; Takahara S; Takei Y; Uno S; Dobashi N; Kobayashi M
    Rinsho Ketsueki; 2003 Jun; 44(6):386-90. PubMed ID: 12884817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
    Bee PC; Gan GG; Teh A; Haris AR
    Med J Malaysia; 2006 Dec; 61(5):547-52. PubMed ID: 17623954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.